ADPGK and colorectal cancer: More recently, in a preclinical study, the TLR7/8 agonist, Resiquimod (R848), and TLR9 agonist, CpG, were combined in a nanoparticle vaccine containing an MHC class I neoantigen (Adpgk) derived from the mouse MC38 colorectal cancer to elicit antitumor T cell responses (83).